Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Isosilybin (Isosilibinin) and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients.
パッケージサイズ | 在庫状況 | 単価(税別) | |||
---|---|---|---|---|---|
サンプルについてお問い合わせ | |||||
1 mg | 在庫あり | ¥ 7,000 | |||
5 mg | 在庫あり | ¥ 16,000 | |||
10 mg | 在庫あり | ¥ 24,000 | |||
25 mg | 在庫あり | ¥ 52,500 | |||
50 mg | 在庫あり | ¥ 97,500 | |||
100 mg | お問い合わせ | ¥ 144,500 | |||
1 mL * 10 mM (in DMSO) | 在庫あり | ¥ 16,500 |
説明 | Isosilybin (Isosilibinin) and Silybin might be suitable candidates to design potent PXR antagonists to prevent drug-drug interactions via CYP3A4 in cancer patients. |
ターゲット&IC50 | CYP3A4:74 μM. |
In vitro | The reporter gene assay demonstrates that the milk thistle constituents silybin and isosilybin inhibit the PXR-mediated induction of CYP3A4, with isosilybin being a more potent inhibitor. Concentrations of 89, 133, and 200 μM of isosilybin decrease CYP3A4 induction by 64, 82, and 88%, respectively, and achieve an IC50 of 74 μM[1]. Additionally, the diastereoisomers isosilybin B and isosilybin A, derived from silymarin, exhibit anti-prostate cancer (PCA) activity through cell cycle arrest and apoptosis induction in human prostate cancer cells LNCaP and 22Rv1[2]. Isosilybin B enhances phosphorylation of Akt and Mdm2, leading to androgen receptor degradation, which is reversed by PI3K inhibitor pretreatment. This process facilitates the formation of a complex that promotes phosphorylation-dependent ubiquitination and subsequent degradation of the androgen receptor[3]. Isosilybin A significantly activates PPARγ at a 30 μM concentration, leading to a concentration-dependent transactivation of a PPARγ-dependent luciferase reporter. In silico docking studies indicate isosilybin A interacts with the receptor's ligand-binding domain through an additional hydrogen bond not found with inactive silymarin constituents[4]. |
細胞研究 | LNCaP cells and 22Rv1 cells are plated and treated at 40–50% confluency with different doses of isosilybin B and isosilybin A (10–90 μM in medium) dissolved originally in Dimethyl sulfoxide (DMSO) for the desired time periods (24–48 h) in serum condition. An equal amount of DMSO (vehicle) is present in each treatment, including control; DMSO concentration did not exceed 0.1% (v/v) in any treatment. At the end of desired treatments, total cell number is determined by counting each sample in duplicate using a hemocytometer under an inverted microscope. Cell viability is determined using trypan blue exclusion method[2]. |
植物由来 |
別名 | Isosilybinin, Isosilibinin, Silymarin, Silybin B, Q-100795 |
分子量 | 482.44 |
分子式 | C25H22O10 |
CAS No. | 72581-71-6 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 88 mg/mL(182.4 mM)
Chloroform, Dichloromethane, Ethyl Acetate: Soluble
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Isosilybin 72581-71-6 Metabolism P450 Isosilybinin Cytochrome P450 Isosilibinin Inhibitor Q 100795 inhibit CYPs Silymarin Silybin B Q100795 Q-100795 inhibitor